Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

Original reporting
Published Nov 18, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 4:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$IPHA
Bearish
high confidence
Mentioned
$IPHA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IPHABearishHigh
01

Why it matters

The data miss expectations, causing a sharp intraday decline and setting a new 52‑week low.

02

Market read

The announcement directly moved the stock, making it a market mover with immediate trading relevance.

03

What to watch

Potential partnership or licensing deals could offset trial disappointment.

Relevance 8/10Novelty 9/10Timing: mid-day trading today

Background

Innate Pharma presented Phase 1 data at a major oncology conference, with expectations set by analysts prior to the readout.

Company-level read

Ticker impact

$IPHABearishHigh confidence
Context

Innate Pharma disclosed Phase 1 trial results for IPH4502 that fell short of expectations, triggering a 21.1% share drop.

Expected impact

downward pressure as investors reassess the drug's commercial potential

Evidence & confidence

Phase 1 data are primary disclosure; modest response rates and high adverse events reduce confidence in future milestones.

Market effects

Biotech sector may see broader risk-off as small‑cap trial failures weigh on sentiment.

US small‑cap biotech stocks could face heightened volatility.

Limited to investors tracking oncology pipelines and biotech ETFs.

Counterpoint

If later-stage data improve, the stock could rebound sharply from oversold levels.

Key entities

  • Innate Pharma

    Biotech firm developing Nectin‑4‑targeting ADCs.

Related articles

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

$IPHAMed

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.